1.	Phase II Study of Melphalan (L-PAM) Plus Buthionine Sulfoximine (BSO) in Patients with Metastatic Melanoma (Summary Last Modified 12/98) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MCGILL-T93-0176, NCI-T93-0176O, T93-0176
2.	Phase II Study of BSO/L-PAM in Relapsed or Refractory Ovarian Cancer (Summary Last Modified 12/2000) Phase: Phase II Type: Treatment Status: Completed Age: over 18 Sponsor: NCI Protocol IDs: FCCC-95126, NCI-T95-0008D, T95-0008
3.	Chemotherapy in Treating Children With Neuroblastoma Phase: Phase I Type: Treatment Status: Completed Age: No greater than 21 at diagnosis Sponsor: NCI, Other Protocol IDs: CDR0000064620, CHLA-95-083, NCI-T95-0092O, T95-0092, NCT00002730
4.	Phase I Study of Buthionine Sulfoximine in Recurrent Acute Myeloblastic Leukemia (Summary Last Modified 05/98) Phase: Phase I Type: Treatment Status: Completed Age: No age specified Sponsor: NCI Protocol IDs: CAN-OCI-97-01-AML01, NCI-T96-0107, T96-0107
5.	Phase I Clinical and Pharmacokinetic Investigation of Intravenous Buthionine Sulfoximine/Melphalan in Patients with Refractory Advanced Solid Tumors Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: OSU-89HO204, NCI-T89-0124C, T89-0124
6.	Phase I Study of Buthionine Sulfoximine with Melphalan in Patients with Solid Tumors or Multiple Myeloma Phase: Phase I Type: Treatment Status: Closed Age: over 18 Sponsor: NCI Protocol IDs: FCCC-88035, NCI-T88-0242D, T88-0242
7.	Phase I Study of Modulation of Glutathione Chemoprotection with Intravenous BSO in Patients Receiving L-PAM for Advanced Malignancies Phase: Phase I Type: Treatment Status: Completed Age: at least 18 Sponsor: NCI Protocol IDs: WCCC-CO-8897, NCI-T88-0189C, T88-0189
8.	Phase I Study of L-PAM/BSO in Patients with Hematologic Malignancies Other Than Acute Leukemia Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: UCCRC-6000, NCI-T90-0175C, T90-0175
9.	Phase I Study of Once-Daily BSO in Patients Receiving Localized Radiotherapy (Summary Last Modified 11/1999) Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MCGILL-ET-9014, NCI-T90-0198O, T90-0198
10.	Phase I Study of Intravenous BSO, Administered as an Initial Bolus Followed by a 24- to 48-Hour Continuous Infusion, Given with Intravenous L-PAM in Patients with Advanced Malignancies Including Melanoma and Ovarian Epithelial Cancer Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: WCCC-CO-9296, NCI-T92-0206D, T92-0206